Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANUS trial of intramuscular allogeneic bone marrow mesenchymal stem cells in systemic sclerosis with refractory digital ulcers
NL-OMON59493Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in systemic sclerosis (SSc), sponsored by University Medical Center Utrecht. Primary endpoint: Treatment toxicity at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON59493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59493.